A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major depressive disorder, according to two complementary papers published recently by researchers at the Icahn School of Medicine at Mount Sinai. In two new research articles, published … Read more
The patient is a 46-year-old Chinese woman. Seven years ago, following a period of psychological stress, she gradually developed low mood and decreased interest, accompanied by feelings of hopelessness, helplessness, and worthlessness. She was diagnosed with moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) [7]. During this period, … Read more
For millions of people, depression is a battle fought with therapy, medication and lifestyle changes but what happens when those treatments don’t work? For nearly half of all individuals diagnosed with major depressive disorder (MDD), this is not just a hypothetical, it is their everyday reality. When depression treatments fail: The hidden struggle of treatment-resistant … Read more
Compared with adults without disabilities, those with disabilities have higher rates of general drug misuse, but information on their misuse of prescription drugs specifically has been lacking. Now, a new analysis has reported that, overall, adults with disabilities are nearly twice as likely to misuse prescription drugs as those without disabilities. Reporting in the American … Read more
Bipolar disorder (BD) is common, affecting some 6 million Americans and 3% of individuals worldwide. Despite its high prevalence, experts say the disorder is poorly understood, underdiagnosed, and underfunded. It’s been more than 50 years since the US Food and Drug Administration (FDA) approved lithium, the best treatment and gold standard for BD. But lithium … Read more
It’s no secret that there is a mental health crisis in the United States. As of 2021, 8.3% adults had major depressive disorder (MDD) and 19.1% had anxiety disorders (AD), and the COVID-19 pandemic exacerbated these statistics. Despite the high prevalence of AD/MDD, diagnosis and treatment rates remain low – 36.9% for AD and 61.0% … Read more
neumora Stock Plunges After Depression Drug Trial Fails Shares of Neumora therapeutics Inc.experienced a record-breaking drop after it’s experimental drug, navacaprant, designed to treat major depressive disorder, failed to demonstrate notable advancement in a pivotal late-stage clinical trial. The news sent shockwaves through the market, highlighting the inherent risks in pharmaceutical advancement. The company announced … Read more
Depression and anxiety are among the most common complications of stroke, affecting 1 in 3 and about 1 in 4 survivors, respectively. These disorders are associated with higher mortality rates, often obscuring the path to recovery. The American Heart Association (AHA)/American Stroke Association (ASA) last published its scientific statement on poststroke depression (PSD) in 2016. … Read more